Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial

Ramucirumab (anti-VEGFR2) plus pembrolizumab (anti-PD1) demonstrated promising antitumor activity and tolerability among patients with previously treated advanced cancers, supporting growing evidence that combination therapies modulating the tumor microenvironment may expand the spectrum of patients...

Full description

Bibliographic Details
Main Authors: Ian Chau, Nicolas Penel, Andres O. Soriano, Hendrik-Tobias Arkenau, Jennifer Cultrera, Rafael Santana-Davila, Emiliano Calvo, Christophe Le Tourneau, Lars Zender, Johanna C. Bendell, Gu Mi, Ling Gao, Samuel Clark McNeely, Joana M. Oliveira, David Ferry, Roy S. Herbst, Charles S. Fuchs
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
gastric/gastroesophageal junction adenocarcinoma
pembrolizumab
phase 1b
ramucirumab
Online Access:https://www.mdpi.com/2072-6694/12/10/2985

Internet

https://www.mdpi.com/2072-6694/12/10/2985

Similar Items